Shire is a holding company. The Company and its subsidiaries is a biopharmaceutical company focused on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT), and regenerative medicine (RM) as well as other therapeutic areas. The Company has three segments: Specialty Pharmaceuticals, which includes VYVANSE/VENVANSE, ADDERALL XR, INTUNIV, and EQUASYM for the treatment of ADHD, as well as LIALDA, PENTASA and RESOLOR for the treatment of GI; HGT, which includes REPLAGAL for Fabry disease, ELAPRASE for Hunter syndrome, VPRIV for Gaucher disease, and FIRAZYR for Hereditary angioedema; and RM, which consist of DERMAGRAFT for diabetic food ulcers.Data provided by Mergent, Inc.
|DR Exchange||NASDAQ Stock Market|
|Effective Date||May 12, 2011|
|Industry||Pharma. & Biotech.|